3,8,11-Trioxa-5-azatridecan-13-oic acid, 2,2-diMethyl-4-oxo-

Base Information

• Chemical Name: 3,8,11-Trioxa-5-azatridecan-13-oic acid, 2,2-diMethyl-4-oxo-
• CAS No.: 108466-89-3
• Molecular Formula: C11H21NO6
• Molecular Weight: 263.291
• Hs Code.: 2934999090
• Mol file: 108466-89-3.mol

Synonyms:3,8,11-Trioxa-5-azatridecan-13-oic acid, 2,2-dimethyl-4-oxo- (9CI);2-[2-[2-[(tert-Butyloxycarbonyl)amino]ethoxy]ethoxy]acetic acid;2-[2-[2-[(tert-Butyloxycarbonyl)amino]ethoxy]ethoxy]acetic acid;

Chemical Property of 3,8,11-Trioxa-5-azatridecan-13-oic acid, 2,2-diMethyl-4-oxo-

Chemical Property:

• Boiling Point: 425.7±30.0 °C(Predicted)
• PKA: 3.40±0.10(Predicted)
• PSA: 97.58000
• Density: 1.145±0.06 g/cm3(Predicted)
• LogP: 0.83330
• Storage Temp.: -20°C

Purity/Quality:

98%,99%, ^*data from raw suppliers

8-tert-Butyloxycarbonylamino-3,6-dioxaoctanoicAcid ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Description: t-Boc-N-amido-PEG2-CH2CO2H is a PEG linker containing a terminal carboxylic acid and Boc-protected amino group. The hydrophilic PEG spacer increases solubility in aqueous media. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. The Boc group can be deprotected under mild acidic conditions to form the free amine.
• Uses: t-Boc-N-amido-PEG2-CH2CO2H is a heterobifunctional, PEGylated crosslinker featuring a Boc-protected amine at one end and a carboxyl group at the other. The hydrophillic PEG linker facilitates solubility in biological applications. t-Boc-N-amido-PEG2-CH2CO2H can be used for bioconjugation or as a building block for synthesis of small molecules, conjugates of small molecules and/or biomolecules, or other tool compounds for chemical biology and medicinal chemistry that require ligation. Examples of applications include its synthetic incorporation into antibody-drug conjugates or proteolysis-targeting chimeras (PROTAC? molecules) for targeted protein degradation.

Technology Process of 3,8,11-Trioxa-5-azatridecan-13-oic acid, 2,2-diMethyl-4-oxo-

There total 152 articles about 3,8,11-Trioxa-5-azatridecan-13-oic acid, 2,2-diMethyl-4-oxo- which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

α-cyclodextrin-Methyl Orange complex (64887-49-6) → methyl orange (547-58-0) + alpha cyclodextrin (10016-20-3)

Guidance literature:

In water; at 25 ℃; Equilibrium constant;

DOI:10.1021/jo00032a036

Reference yield:

C36H60O30*C9H7NO6 → 4-(acetyloxy)-3-nitrobenzoic acid (1210-97-5) + alpha cyclodextrin (10016-20-3)

Guidance literature:

With phosphate buffer; at 25 ℃; Equilibrium constant;

DOI:10.1021/jo00243a055

Reference yield:

C36H60O30*C11H11NO6 → 4-carboxy-2-nitrophenyl butanoate (56003-42-0) + alpha cyclodextrin (10016-20-3)

Guidance literature:

With phosphate buffer; at 25 ℃; Equilibrium constant;

DOI:10.1021/jo00243a055

upstream raw materials:

bromoacetic acid

2-(2-tert-butyloxycarbonylaminoethoxy)ethanol

monosodium iodoacetate

di-tert-butyl dicarbonate

Downstream raw materials:

C₃₄H₄₇ClN₆O₈

1-((R)-9-amino-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-3,11-dioxo-13,16-dioxa-2,8,10-triazaoctadec-9-en-18-yl)-4-((E)-2-(1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinolin-9-yl)ethenyl)-2,6-dimethylpyridinium hydrotrifluoroacetate trifluoroacetate

1-((R)-9-amino-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-3,11-dioxo-13,16-dioxa-2,8,10-triazaoctadec-9-en-18-yl)-4-((1E,3E)-4-(4-(dimethylamino)phenyl)buta-1,3-dienyl)-2,6-dimethylpyridinium hydrotrifluoroacetate trifluoroacetate

Refernces

• 1、 Richardson, Paul L.,Marin, Violeta L.,Koeniger, Stormy L.,Baranczak, Aleksandra,Wilsbacher, Julie L.,Kovar, Peter J.,Bacon-Trusk, Patricia E.,Cheng, Min,Hopkins, Todd A.,Haman, Sandra T.,Vasudevan, Anil. "Controlling cellular distribution of drugs with permeability modifying moieties". . p. 974 - 984. Retrieved 2019.
• 2、 Zhang, Yan,So, Min-Kyung,Loening, Andreas M.,Yao, Hequan,Gambhir, Sanjiv S.,Rao, Jianghong. "HaloTag protein-mediated site-specific conjugation of bioluminescent proteins to quantum dots". . p. 4936 - 4940. Retrieved 2006.
• 3、 -. "DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE". Paragraph 0240; 0242. . Retrieved 2021/02/05.
• 4、 -. "Method for preparing semaglutide side chain by liquid phase method". Paragraph 0077-0079; 072. . Retrieved 2020/07/02.